These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 31655267)

  • 1. Neuromyelitis optica spectrum disorder after treatment with pembrolizumab.
    Shimada T; Hoshino Y; Tsunemi T; Hattori A; Nakagawa E; Yokoyama K; Hattori N
    Mult Scler Relat Disord; 2020 Jan; 37():101447. PubMed ID: 31655267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case report of neuromyelitis optica spectrum disorder induced by pembrolizumab treatment for lung adenocarcinoma: a clinical and immunohistochemical study.
    Hirano S; Kojima A; Nakayama Y; Takeda T; Kishimoto T; Takahashi T; Kuwabara S; Mori M
    BMC Neurol; 2022 Dec; 22(1):483. PubMed ID: 36517738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial on: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.
    Pardo S; Giovannoni G; Hawkes C; Lechner-Scott J; Waubant E; Levy M
    Mult Scler Relat Disord; 2019 Aug; 33():A1-A2. PubMed ID: 31324299
    [No Abstract]   [Full Text] [Related]  

  • 4. Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report.
    Narumi Y; Yoshida R; Minami Y; Yamamoto Y; Takeguchi S; Kano K; Takahashi K; Saito T; Sawada J; Terui H; Katayama T; Sasaki T; Ohsaki Y
    BMC Cancer; 2018 Jan; 18(1):95. PubMed ID: 29361915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuromyelitis optica associated with the use of Atezolizumab in a patient with advanced lung adenocarcinoma.
    Pedrero Prieto M; Gorriz Romero D; Gómez Roch E; Pérez Miralles FC; Casanova Estruch B
    Neurol Sci; 2024 May; 45(5):2199-2202. PubMed ID: 38091210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
    Pittock SJ; Lennon VA; McKeon A; Mandrekar J; Weinshenker BG; Lucchinetti CF; O'Toole O; Wingerchuk DM
    Lancet Neurol; 2013 Jun; 12(6):554-62. PubMed ID: 23623397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two Cases of Pediatric AQP4-Antibody Positive Neuromyelitis Optica Spectrum Disorder Successfully Treated with Tocilizumab.
    Breu M; Glatter S; Höftberger R; Freilinger M; Kircher K; Kasprian G; Seidl R; Kornek B
    Neuropediatrics; 2019 Jun; 50(3):193-196. PubMed ID: 30913570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD) coexisting with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis: A case report and literature review.
    Tao S; Zhang Y; Ye H; Guo D
    Mult Scler Relat Disord; 2019 Oct; 35():185-192. PubMed ID: 31398657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuromyelitis Optica Spectrum Disorder with Recurrent Intracranial Hemorrhage.
    Yaguchi H; Mito Y; Ohashi I; Nomura T; Yabe I; Tajima Y
    Intern Med; 2017; 56(13):1729-1732. PubMed ID: 28674367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refractory neuromyelitis optica spectrum disorder in systemic lupus erythematosus successfully treated with rituximab.
    Shidahara K; Hayashi K; Sada KE; Hiramatsu S; Morishita M; Watanabe H; Matsumoto Y; Kawabata T; Wada J
    Lupus; 2018 Jul; 27(8):1374-1377. PubMed ID: 29498304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab-induced interstitial lung disease in a patient with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder.
    Ahn SH; Kim SM; Sung JJ
    Mult Scler Relat Disord; 2018 Feb; 20():192-193. PubMed ID: 29414297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production.
    Cotzomi E; Stathopoulos P; Lee CS; Ritchie AM; Soltys JN; Delmotte FR; Oe T; Sng J; Jiang R; Ma AK; Vander Heiden JA; Kleinstein SH; Levy M; Bennett JL; Meffre E; O'Connor KC
    Brain; 2019 Jun; 142(6):1598-1615. PubMed ID: 31056665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inebilizumab for treatment of neuromyelitis optica spectrum disorder.
    J Tullman M; Zabeti A; Vuocolo S; Dinh Q
    Neurodegener Dis Manag; 2021 Oct; 11(5):341-352. PubMed ID: 34486379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mild COVID-19 infection despite chronic B cell depletion in a patient with aquaporin-4-positive neuromyelitis optica spectrum disorder.
    Creed MA; Ballesteros E; Jr LJG; Imitola J
    Mult Scler Relat Disord; 2020 Sep; 44():102199. PubMed ID: 32554285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders.
    Duchow A; Paul F; Bellmann-Strobl J
    Expert Opin Biol Ther; 2020 Sep; 20(9):1061-1072. PubMed ID: 32228250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Presence of anti-Ro/SSA antibody may be associated with anti-aquaporin-4 antibody positivity in neuromyelitis optica spectrum disorder.
    Park JH; Hwang J; Min JH; Kim BJ; Kang ES; Lee KH
    J Neurol Sci; 2015 Jan; 348(1-2):132-5. PubMed ID: 25500159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inebilizumab: First Approval.
    Frampton JE
    Drugs; 2020 Aug; 80(12):1259-1264. PubMed ID: 32729016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models.
    Wu Y; Zhong L; Geng J
    Mult Scler Relat Disord; 2019 Jan; 27():412-418. PubMed ID: 30530071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies.
    Sepúlveda M; Sola-Valls N; Escudero D; Rojc B; Barón M; Hernández-Echebarría L; Gómez B; Dalmau J; Saiz A; Graus F
    Mult Scler; 2018 Nov; 24(13):1753-1759. PubMed ID: 28920766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aquaporin-4-antibody-positive Neuromyelitis Optica Spectrum Disorder in a Patient with Charcot-Marie-Tooth Disease Type 1A.
    Hamada Y; Takahashi K; Kanbayashi T; Hatanaka Y; Kobayashi S; Sonoo M
    Intern Med; 2021 May; 60(10):1611-1614. PubMed ID: 33361678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.